Navigation Links
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Date:11/1/2011

b interferon-free trial of PSI-7977 and/or PSI-938 in patients with all HCV genotypes. Mericitabine (RG7128) continues in development through a strategic collaboration with Roche.

   Contact
       Richard E. T. Smith, Ph.D.
       VP, Investor Relations and Corporate Communications
       Office +1 (609) 865-0693

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ... today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") ... 2014. The terms of the acquisition were not disclosed. ... ("DME") company providing a wide range of sleep, mobility, and ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... New Jersey, October 7, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... ZMH and SIX: ZMH) announced today its ... broadcast live over the Internet on Thursday, Oct. 28, 2010, ... quarterly results will be made available at 7:00 a.m. Eastern ... The live audio webcast can be accessed via Zimmer,s Investor ...
Cached Medicine Technology:International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 2International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 3International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 4International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 5International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 6International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 7International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network 8Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2010 Results 2
(Date:4/18/2014)... being prepped to enter the battle against infectious ... diseases in remote areas, thanks in part to ... the International Space Station on the behavior of ... capillary flow to diagnose infectious diseases such as ... researcher at Northwestern University in Evanston, Ill., had ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... MDTH ) announced that its senior management will give ... January,7 - 10, 2008 at the Westin St. Francis ... give its presentation on Thursday,January 10, 2008 at 10:00 ... the Internet via MedCath,s website (http://www.medcath.com ) and,will ...
... Show with, Fashions by Chloe Dao, Presented by Rachel Hunter, Benefiting Dress ... ... Culminating a year of,empowering women to ,find their slim, and supporting the ... with the Style Your Slim(SM) Fashion Show in Los Angeles, CA, on,January 8th. ...
... SOUTH WINDSOR, Conn., Jan. 2 Gerber,Scientific, Inc. (NYSE: ... announced that Marc T. Giles, President and Chief Executive,Officer, ... Conference,being held in New York on Tuesday, January 8, ... of the presentation will be available on the home ...
... of Aetna, Inc., LOVELAND, Colo., Jan. 2 ... that Ms. Louise McCormick has joined the,company,s Board ... "We pride ourselves on our commitment to excellence ... quality, independent Directors,is critical to this effort," said ...
... finds whites are prescribed opioids more often than blacks, Hispanics ... in an emergency room in significant pain, you are less ... if you are not white, new research shows. , The ... that minorities don,t get effective pain treatment in the ER ...
... benefits outweigh its risks , , WEDNESDAY, Jan. 2 (HealthDay ... cause high blood pressure in patients with kidney cancer, ... of a study published last month that found the ... failure among patients with stomach cancer. , "Patients taking ...
Cached Medicine News:Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 2Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 3Health News:Slim-Fast Celebrates Weight Loss by Hosting Style Your Slim(SM) Fashion Show Featuring Real Women 4Health News:Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 2Health News:Louise McCormick Joins Heska's Board of Directors 2Health News:Louise McCormick Joins Heska's Board of Directors 3Health News:Minorities Less Likely to Get Powerful Painkillers in ER 2Health News:Minorities Less Likely to Get Powerful Painkillers in ER 3Health News:New Cancer Drug Boosts Blood Pressure 2Health News:New Cancer Drug Boosts Blood Pressure 3
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Medicine Products: